telbivudine (Tyzeka)

Unknown / undisclosed

Also known as LDT-600

DiscontinuedHBV polymerase (reverse transcriptase)No recent registered activity
WithdrawnUS approval

Evidence outlook · regulatory status

US approval withdrawn: Chronic Hepatitis B (FDA, approved 2006-10-25)

The FDA approved this product and later withdrew the approval, so it has no current US approval. The withdrawal took effect on 2019-10-09. The holder told FDA the product was no longer marketed and asked FDA to withdraw the approval (21 CFR 314.150(c)); FDA states that such a withdrawal is without prejudice to refiling. Development was discontinued, as a strategic decision by the sponsor. The trials below are the product's evidence history.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (15)
Other / comorbidity
NCT02058108 · Novartis Pharmaceuticals
2014-10-31 – 2019-01-09 · Chronic Hepatitis B
What this study did
NCT01595685 · Asan Medical Center
2012-05 – 2014-12 · Chronic Viral Hepatitis B Without Delta-agent
What this study did
NCT01270165 · Yonsei University
2010-06 – 2012-05 · Chronic Hepatitis B
What this study did
NCT00805675 · Novartis Pharmaceuticals
2008-11 – 2010-12 · Hepatitis B Virus
What this study did
NCT00640588 · Novartis Pharmaceuticals
2008-03 – 2009-12 · Hepatitis B, Chronic
What this study did
NCT00142298 · Novartis Pharmaceuticals
2005-03 – 2009-11 · Chronic Hepatitis B
What this study did
NCT00376259 · Novartis
2007-01 – 2008-08 · Hepatitis B
What this study did
NCT00412529 · Novartis Pharmaceuticals
2006-12 – 2008-02 · Hepatitis B, Chronic Hepatitis B
What this study did
NCT00275652 · Mayo Clinic
2004-06 – 2007-08 · Hepatitis B, Cirrhosis
What this study did
NCT00131742 · Novartis
2004-07 – 2007-01 · Chronic Hepatitis B
What this study did
NCT00132652 · Novartis
2005-02 – 2006-12 · Chronic Hepatitis B
What this study did
NCT00115245 · Novartis
2004-11 – 2006-08 · Chronic Hepatitis B
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT02447705 · Chang Gung Memorial Hospital
2013-06 – 2017-01-31 · Disorder Related to Transplantation, Virus Diseases, Injury Due to Exposure to External Cause
What this study did
NCT01204827 · Hadassah Medical Organization
— · Chronic Hepatitis B
What this study did
Phase 2 (3)
Other / comorbidity
NCT00804622 · The University of Hong Kong
2008-12 – 2010-03 · Chronic Hepatitis B
What this study did
NCT00128544 · Novartis
2005-05 – 2007-05 · Hepatitis B
What this study did
NCT00124241 · Novartis
est. completion 2005-11 · Hepatitis B
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT02338674 · Fuzhou General Hospital
2014-10 – 2017-10 · Hepatitis B, Chronic
What this study did
Phase 1 (1)
Other / comorbidity
NCT00907894 · Novartis Pharmaceuticals
2009-02 – 2012-03 · Chronic Hepatitis B
What this study did
Phase 4 (31)
Other / comorbidity
NCT02774837 · Seng Gee Lim
2016-04 – 2020-07 · Chronic Hepatitis B
What this study did
NCT03778567 · The University of Hong Kong
2013-08-01 – 2018-05-31 · Hepatitis B, Chronic, Chronic Kidney Diseases
What this study did
NCT03468907 · Third Affiliated Hospital, Sun Yat-Sen University
2015-06-01 – 2017-12-31 · Hepatitis B, Chronic
What this study did
NCT02826070 · Nanfang Hospital, Southern Medical University
2015-04 – 2017-10 · Hepatitis B, Chronic
What this study did
NCT00810524 · Sun Yat-sen University
2007-01 – 2017-01 · Hepatitis B, Chronic
What this study did
NCT01379508 · Novartis Pharmaceuticals
2011-03-21 – 2015-12-10 · Chronic Hepatitis B
What this study did
NCT01529255 · Nanfang Hospital, Southern Medical University
2011-08 – 2015-12 · Hepatitis B, Chronic
What this study did
NCT02894554 · National Taiwan University Hospital
2014-07 – 2015-07 · HBsAg-positive Renal Allograft Recipients
What this study did
NCT01799486 · Lin Bingliang
2013-02 – 2015-03 · HBV-related Liver Cirrhosis
What this study did
NCT01588912 · Pusan National University Yangsan Hospital
2012-04 – 2014-12 · Chronic Hepatitis B
What this study did
NCT01637844 · Yi-Hua Zhou
2012-04 – 2014-10 · HBV
What this study did
NCT01521975 · Third Affiliated Hospital, Sun Yat-Sen University
2011-01-01 – 2014-05-30 · Hepatitis B, Chronic
What this study did
NCT01693679 · Shao-quan Zhang
2012-09 – 2014-04 · HBV-related Liver Cirrhosis
What this study did
NCT01380951 · The Fifth People's Hospital of Suzhou
2011-05 – 2013-12 · Liver Cirrhosis, Chronic Hepatitis B
What this study did
NCT01788371 · Hua Zhang
2009-03 – 2013-07 · Hepatitis B Infection, Chronic Infection, Viremia
What this study did
NCT01743079 · Beijing YouAn Hospital
2009-01 – 2013-07 · Chronic Hepatitis B, Late Pregnancy, Transmission, Complication
What this study did
NCT00962533 · Nanfang Hospital, Southern Medical University
2009-08 – 2012-08 · Hepatitis B, Chronic
What this study did
NCT00651209 · Novartis Pharmaceuticals
2008-02 – 2011-12 · Hepatitis B, Chronic
What this study did
NCT00537537 · Novartis Pharmaceuticals
2007-08 – 2011-06 · Hepatitis B, Chronic
What this study did
NCT00862706 · Novartis Pharmaceuticals
2009-04 – 2011-04 · Compensated Chronic Hepatitis B
What this study did
NCT00877149 · Novartis Pharmaceuticals
2009-03 – 2011-04 · Compensated Chronic Hepatitis B
What this study did
NCT00409019 · Novartis Pharmaceuticals
est. completion 2011-03 · Chronic Hepatitis B
What this study did
NCT00939068 · Southeast University, China
2008-02 – 2010-11 · Chronic Hepatitis B, Gestation
What this study did
NCT00781105 · Novartis Pharmaceuticals
2008-08-01 – 2010-09-16 · Chronic Hepatitis B
What this study did
NCT01337791 · Southeast University, China
2008-08 – 2009-12 · Chronic Hepatitis B, Pregnancy Complications, High Viral Load, Elevated Alanine Aminotransferase Levels
What this study did
NCT00606099 · Novartis
2007-11 – 2009-11 · Chronic Hepatitis B
What this study did
NCT00467545 · Novartis Pharmaceuticals
2007-04 – 2009-09 · Chronic Hepatitis B
What this study did
NCT00710216 · University of Ulm
— · Hepatitis B, Chronic
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT00051090 · National Institute of Allergy and Infectious Diseases (NIAID)
— · HIV Infections, Hepatitis B
What this study did
NCT02049736 · Chinese University of Hong Kong
2013-12 – 2015-06 · Chronic Hepatitis B
What this study did
NCT01480492 · Cz Li
2010-01 – 2011-10 · HBeAg Positive Chronic Hepatitis B Infection
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1/2 (1)
Other / comorbidity
NCT02615639 · Third Affiliated Hospital, Sun Yat-Sen University
2015-11 – 2018-11 · Chronic Hepatitis B
What this study did
Phase 4 (2)
Other / comorbidity
NCT01005238 · University Hospital, Basel, Switzerland
2009-09 – 2014-12 · Hepatitis, Chronic
What this study did
NCT01597934 · Yonsei University
2012-08 – 2014-05 · Chronic Hepatitis B
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT01732224 · Institute of Liver and Biliary Sciences, India
2012-11 – 2014-04 · Spontaneous Reactivation of Hepatitis B
What this study did
NCT01260610 · Institute of Liver and Biliary Sciences, India
2011-06 – 2011-06 · Chronic Hepatitis B
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, 6 of them ahead of this one.

This drug's own stage for Chronic Hepatitis B: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Telbivudine (Tyzeka): this drugDiscontinued—HBV polymerase (reverse transcriptase)not yet graded
NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed
Entecavir (Baraclude)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Hepatitis B Immune Globulin (HepaGam B)ApprovedProtein / enzyme therapeuticHBsAgnot yet gradedNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
Lamivudine (Epivir-HBV)
ApprovedUS marketing discontinued
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Peginterferon Alfa-2a (Pegasys)Approved—Type I interferon receptorPartial signalFeatured results are non-efficacy only in this race
Tenofovir Alafenamide (Vemlidy)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)Reliable signalFeatured results are non-efficacy only in this race
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Reliable signal
NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants
NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants
Besifovir Dipivoxil (Besivo)Phase 3Small moleculeHBV polymerase (reverse transcriptase)Partial signal
NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019).
Hepatitis B Immune Globulin (I.V.-Hepabig)Phase 3Polyclonal Antibody (human Hepatitis B Immunoglobulin)HBsAgnot yet gradedNo reviewed efficacy summary in this indication
Tenofovir Amibufenamide (Hengmu)Phase 3Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
TQA3605Phase 3—HBV core proteinnot yet gradedNo reviewed efficacy summary in this indication
TVAX-008Phase 3VaccineHepatitis B virus antigens (HBsAg + HBcAg)not yet gradedNo reviewed efficacy summary in this indication
AHB-171Phase 2RNA / oligonucleotideHBV RNAnot yet gradedNo reviewed efficacy summary in this indication
Daplusiran / TomligisiranPhase 2RNA / oligonucleotideHBV RNA (X and S transcripts)not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
HepalatidePhase 2PeptideNTCPnot yet gradedNo reviewed efficacy summary in this indication
Libevitug (HH-003)Phase 2Monoclonal antibodyHBV/HDV large envelope protein (PreS1 domain)not yet gradedNo reviewed efficacy summary in this indication
MetacavirPhase 2Small moleculeHBV reverse transcriptase (nucleoside analog)not yet gradedNo reviewed efficacy summary in this indication
REP 2139-MgPhase 2—HBsAg release (nucleic acid polymer)not yet gradedNo reviewed efficacy summary in this indication
T101Phase 2Biologic (subtype unspecified)HBV core, polymerase and envelope antigensnot yet gradedNo reviewed efficacy summary in this indication
TQA3810Phase 2—TLR8not yet gradedNo reviewed efficacy summary in this indication
CRMA-1001Phase 1/2Gene therapy / editingHBV genome (cccDNA and integrated DNA)not yet gradedNo reviewed efficacy summary in this indication
HepadvaxPhase 1/2VaccineHBsAg (PreS) immunizationnot yet gradedNo reviewed efficacy summary in this indication
Human Serum Albumin / Interferon Alpha2b Fusion ProteinPhase 1/2Biologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
LW231Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
PA1010Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
TQA3038Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
ACT201Phase 1RNA / oligonucleotideHBsAgnot yet gradedNo reviewed efficacy summary in this indication
CB06-036Phase 1—TLR8not yet gradedNo reviewed efficacy summary in this indication
DA-2803Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Entecavir (Cavir)
Phase 1(overall)
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
HECN30227Phase 1——not yet gradedNo reviewed efficacy summary in this indication
SA1211Phase 1RNA / oligonucleotideHepatitis B virus RNA (dual-target siRNA)not yet gradedNo reviewed efficacy summary in this indication
TVAX-028Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Adefovir Dipivoxil (Hepsera)DiscontinuedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Obeticholic Acid (Ocaliva)Discontinued—FXRnot yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 October 2019WithdrawalFDA withdraws approval of NDA 022011 (Federal Register 2019-19348)
US, FDA · Source ↗